FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Ciaffoni Joseph</u>						2. Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL, INC COLL									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
															V Director	Director		10% Ow	ner	
(Last)	(Fi	irst)	(Middle)		- L	[GOED]									Officer below)	(give title		Other (s below)	pecify	
C/O COLLEGIUM PHARMACEUTICAL, INC.							3. Date of Earliest Transaction (Month/Day/Year)									President and CEO				
780 DEDHAM STREET, SUITE 800						07/01/2018														
/00 DEDITAWI STREET, SOTTE 000							4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable				
(Street)						4. II Amendment, Date of Original Filed (Month/Day/Year)									b. Individual of Joint/Group Filling (Check Applicable Line)					
CANTON MA 02021															X Form filed by One Reporting Person					
				.										Form filed by More than One Reporting						
(City) (State) (Zip)														Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of S	Security (Inst	tr. 3)		2. Trans	action	, [2A. Deeme	ed	3.		4. Securi				5. Amou	nt of	6. Ow	nership 7	7. Nature	
Date (Month/Da					Day/Ye	ear)	Execution Date, if any (Month/Day/Year)		Transaction Code (Instr. r) 8)		Disposed Of (D) (Instr. 3, 5)		3, 4 and	Securitie Beneficia Owned F	ally (D)		or Indirect	of Indirect Beneficial Ownership		
									Code	v	Amount	((A) or (D) Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 07/01/2						2018			A		25,140	_	A	\$0	113,341			D		
		-	Fable II	Dorivo	tivo	Soo	urition	Λοαι	irod D	ione	sood of	or P	onof	ioially	Owned					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
															11. Nature					
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	Execution E if any (Month/Day	Date,	ransaction Code (Instr.		of		Expiration Date (Month/Day/Year)			of Securities Underlying Derivative Security (Instr. 3 and 4)			Derivative Security (Instr. 5)	derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisabl		xpiration vate	Title	0 0	Amount or Jumber of Shares						
Stock Option (Right to	\$23.85	07/01/2018			A		41,418		(2)	0	7/01/2028	Comm		1,418	\$0	41,418	3	D		

Explanation of Responses:

Remarks:

/s/ Paul Brannelly as Attorney-In-Fact For Joseph Ciaffoni

07/02/2018

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} Reflects the grant of restricted stock units in connection with the reporting person's promotion to Chief Executive Officer of the issuer. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on July 1, 2019, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.

^{2.} Twenty-five percent (25%) of the option vests and becomes exercisable on July 1, 2019, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer.